New application of pentacyclic triterpene structure modified compound in preparation of medicine for inhibiting atopic dermatitis

The pentacyclic triterpene structural modification compound CKBA inhibits mast cell activation and degranulation, solving the high side effects and high cost in the treatment of atopic dermatitis, and provides a safe and effective treatment plan to improve skin symptoms.

CN118924765APending Publication Date: 2024-11-12SUZHOU BOTANY BIOMEDICALS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310572234.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2023-05-19
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing atopic dermatitis treatment drugs have high side effects, high cost and unfavorable long-term use, and their pathogenesis has not been fully elucidated, and new treatment plans are urgently needed.

Method used

Using pentacyclic triterpene structural modification compounds, especially 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid (CKBA), prevents the degranulation effect by inhibiting mast cell activation and CD107a expression, and is used to prepare soft ointments. Preparation is treated topically.

Benefits of technology

Effectively alleviate and treat atopic dermatitis, reduce mast cell activation and degranulation, improve skin dryness and itching symptoms, and provide safer, more effective and less costly treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004243574900000021
    Figure BDA0004243574900000021
  • Figure BDA0004243574900000051
    Figure BDA0004243574900000051
  • Figure BDA0004243574900000131
    Figure BDA0004243574900000131
Patent Text Reader

Abstract

The invention provides a novel application of a pentacyclic triterpene structure modified compound in preparation of a medicine for inhibiting atopic dermatitis. The invention reveals that the pentacyclic triterpene structure modified compound can effectively treat atopic dermatitis with unique pathogenesis for the first time. The pentacyclic triterpene structure modified compound can also be used for inhibiting the activation of mast cells, especially inhibiting the degranulation of mast cells and the expression of mast cell surface activation marker CD107a. The invention also provides a particularly preferable external preparation which is an ointment preparation. The invention provides a new way for relieving and treating atopic dermatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medicine, and more specifically, the present invention relates to a novel use of a pentacyclic triterpene structure-modified compound in the preparation of a drug for inhibiting atopic dermatitis. Background Art

[0002] Atopic dermatitis (AD), also known as allergic contact dermatitis, is an allergic skin inflammation. The manifestations of the inflammatory response include skin itching, redness, swelling, blistering, exudation, dry skin, cracking, etc.

[0003] According to global data, the prevalence of atopic dermatitis varies greatly between countries and regions, and is particularly common in children. The incidence of atopic dermatitis is also affected by factors such as geographic region and season. Currently, the prevalence of atopic dermatitis remains high.

[0004] According to the latest Chinese Atopic Dermatitis Diagnosis and Treatment Guidelines (2020 edition), atopic dermatitis presents a chronic course with diverse clinical manifestations. The most basic characteristics are dry skin, chronic eczematous skin lesions and obvious itching, and show age-related disease manifestations: Infancy: The lesions are mainly acute eczematous, gradually spreading to the extensor side of the limbs; Childhood: Subacute and chronic lesions are the main manifestations, and the rash is often dry and thickened, with obvious lichenification; Adolescence and Adulthood: The lesions are similar to those in childhood, and most parts show dry and hypertrophic dermatitis lesions; Old Age: It has gradually received attention in recent years, and the rash is usually severe and annoying.

[0005] The pathogenesis of atopic dermatitis involves many factors, but it has not yet been fully elucidated. It is prone to recurrence. Although it does not affect physical health, it imposes a huge psychological burden on patients, seriously affecting their quality of life and easily causing a variety of psychological symptoms or diseases. Therefore, atopic dermatitis is one of the important research topics in the field of skin diseases in the world.

[0006] In the pathogenesis of atopic dermatitis, mast cells also play an important role. Mast cells exist in the skin and other tissues. They play a role in promoting lesions in atopic dermatitis, mainly by releasing a variety of inflammatory mediators, such as histamine, leukotriene B4, vasoactive intestinal peptide, etc. These inflammatory mediators can promote vasodilation and increased permeability in the lesion site, leading to symptoms such as skin redness, edema and itching (Maurer, M., & Theoharides, TC, 2007, 127 (3), 481-484).

[0007] As an allergic skin inflammation, atopic dermatitis manifests itself as dry and thickened skin, accompanied by a typical significant increase in IgE levels in the body and obvious itching symptoms. Its pathogenesis is completely different from that of psoriasis and other diseases that are almost entirely dominated by T cells and have nothing to do with IgE.

[0008] First-line treatments for atopic dermatitis include topical glucocorticoids, calcium-regulated neurotransmitter antagonists, phosphatase-4 inhibitors, etc. Among them, topical medications are mainly steroid drugs (mainly used to relieve inflammation and itching, but long-term use can lead to side effects such as thinning of the skin, vasodilation, and increased risk of infection) and non-steroidal drugs (such as calmodulin inhibitors (Tacrolimus and Pimecrolimus), which have less risk of skin atrophy and infection, but may cause local irritation and pain). In addition, there are also oral medications and biological agents, such as cetirizine or Dupilumab, which have more obvious effects on reducing inflammation and relieving itching, but are not conducive to long-term use due to side effects or high prices.

[0009] Therefore, there is an urgent need to find new drugs for the treatment of atopic dermatitis in this field, so as to provide the majority of atopic dermatitis patients with safer, more effective, less side-effect and lower-cost therapeutic drugs. Summary of the invention

[0010] The object of the present invention is to provide a new use of a pentacyclic triterpene structure-modified compound in the preparation of a drug for inhibiting atopic dermatitis.

[0011] The present invention also aims to provide a new use of a pentacyclic triterpene structure-modified compound, which is to inhibit the differentiation of mast cells; in particular, to inhibit the expression of CD107a and mast cell degranulation.

[0012] Another object of the present invention is to provide a particularly preferred external preparation, which is an ointment preparation.

[0013] In the first aspect of the present invention, there is provided the use of a compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof, for preparing a pharmaceutical composition for relieving or treating atopic dermatitis;

[0014]

[0015] Wherein, R is independently selected from: hydrogen, hydroxyl, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen.

[0016] In one or more embodiments, the atopic dermatitis is caused by mast cell activation leading to degranulation effect.

[0017] In one or more embodiments, the atopic dermatitis is atopic dermatitis caused by mast cell activation leading to degranulation effect.

[0018] In one or more embodiments, the atopic dermatitis is atopic dermatitis caused by mast cell activation leading to high expression of CD107a.

[0019] In another aspect of the present invention, there is provided the use of a compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof, for preparing a composition (such as a cell culture medium or a pharmaceutical composition) for inhibiting mast cell activation.

[0020] In one or more embodiments, the inhibition of mast cell activation is: inhibiting the expression of CD107a on the surface of mast cells.

[0021] In one or more embodiments, the inhibition of mast cell activation is: inhibition of mast cell degranulation.

[0022] In one or more embodiments, the pharmaceutical composition is in an external dosage form.

[0023] In one or more embodiments, the dosage form of the pharmaceutical composition includes (but is not limited to) selected from: ointments (such as creams, pastes), gels, foams, sprays, powders, creams; more preferably, the dosage form of the pharmaceutical composition is an ointment (such as creams, pastes).

[0024] In one or more preferred embodiments, the composition is an ointment, comprising: (a) a compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof; and (b) white vaseline, light liquid paraffin, isopropyl myristate, and vitamin E.

[0025] In one or more preferred embodiments, the ointment comprises:

[0026] (a) Compound: 0.3-3 parts by weight, preferably 0.4-2 parts by weight (e.g., 0.5, 0.7, 0.8, 0.9, 1, 1.2, 1.4, 1.5, 1.6, 1.8 parts by weight, etc.);

[0027] White vaseline: 65-85 parts by weight, preferably 68-82 parts by weight (e.g., 70, 72, 74, 75, 76, 78, 80 parts by weight, etc.);

[0028] Light liquid paraffin: 2-9 parts by weight, preferably 3-8 parts by weight (such as 4, 5, 6, 7 parts by weight, etc.);

[0029] Isopropyl myristate: 12-30 parts by weight, preferably 15-25 parts by weight (e.g., 16, 18, 20, 22, 24 parts by weight, etc.);

[0030] Vitamin E: 0.01-0.05 parts by weight, preferably 0.012-0.04 parts by weight (e.g., 0.015, 0.018, 0.02, 0.025, 0.03, 0.035 parts by weight, etc.).

[0031] In one or more embodiments, the pharmaceutical composition includes (but is not limited to) selected from: glycerol, propylene glycol, carbomer, triethanolamine, sodium carboxymethyl cellulose, water, or a combination thereof.

[0032] In one or more embodiments, the pharmaceutical composition comprises a mixture of glycerol, propylene glycol, and carbomer.

[0033] In one or more embodiments, the glycerin, propylene glycol and carbomer are mixed in a ratio of 4:4:3, and each carrier component may fluctuate by 30% (preferably 25%, 20%, 10% or 5%).

[0034] In one or more embodiments, the concentration of the compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salts in the pharmaceutical composition is 0.01-3% (further preferably 0.02-2%; more preferably 0.05-1.5%; such as 0.1%, 0.2%, 0.3%, 0.5%, 0.8%, 1%, 1.2%, 1.3%, etc.).

[0035] In one or more embodiments, the compound of formula (I) is prepared by the following method: using 11-carbonyl-β-acetyl boswellic acid as a raw material, replacing its AcO- group with Group.

[0036] In one or more embodiments, the compound of formula (I) is prepared by the following method:

[0037] (i) using 11-carbonyl-β-acetylboswellic acid as a raw material and reacting it with a base to obtain 11-carbonyl-β-boswellic acid; and

[0038] (ii) reacting 11-carbonyl-β-boswellic acid with cyclohexanecarbonyl chloride to obtain a compound represented by formula (I).

[0039] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salts are used as the main active ingredient (active component) in the composition (including pharmaceutical composition).

[0040] In one or more embodiments, the compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salts is used as the only active ingredient (active component) in the composition (including pharmaceutical composition).

[0041] In one or more embodiments, the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof can be used in combination with other active ingredients, each exerting an independent effect.

[0042] In one or more embodiments, the compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof can be used in combination with other active ingredients, and the combination of two or more ingredients can exert a synergistic effect.

[0043] In another aspect of the present invention, a method for preparing a pharmaceutical composition for relieving or treating atopic dermatitis is provided, comprising: mixing (a) a compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof, and (b) white vaseline, light liquid paraffin, isopropyl myristate, and vitamin E to prepare an ointment, wherein the content of each component is as described above.

[0044] In another aspect of the present invention, a method for inhibiting mast cell activation is provided, the method comprising: treating mast cells with a compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof, thereby inhibiting mast cell activation.

[0045] In one or more embodiments, the inhibition of mast cell activation is: inhibiting mast cell activation (high expression of CD107a); and / or inhibiting the degranulation effect of mast cell activation (producing β-hexokinase).

[0046] In one or more embodiments, the methods maintain mast cells in a mature state.

[0047] In one or more embodiments, the method of inhibiting mast cells is an in vitro method.

[0048] In one or more embodiments, the method of inhibiting mast cells is to inhibit an in vitro mast cell culture / cell population (such as an enriched cell population or a passaged cell population).

[0049] In one or more embodiments, the method of inhibiting mast cells is a method that is not directly aimed at treating a disease (a non-therapeutic method).

[0050] In another aspect of the present invention, a method for alleviating or treating atopic dermatitis is provided, the method comprising: administering an effective amount of a compound represented by formula (I) or its isomers, solvates or precursors, or pharmaceutically acceptable salts thereof to a subject in need of treatment; or administering an effective amount of the pharmaceutical composition to a subject in need of treatment.

[0051] In one or more embodiments, the compound represented by formula (I) has a structure represented by formula (II).

[0052]

[0053] The English name of the compound of formula (II) is 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, abbreviated as CKBA.

[0054] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 , 5 μM CKBA compounds inhibit mast cell degranulation and β-hexosaminidase production in vitro.

[0056] Figure 2 , 5 μM CKBA compounds inhibited the expression of CD107a by mast cells in vitro.

[0057] Figure 3 , CKBA gel was used to treat the atopic dermatitis animal model, which effectively improved the atopic dermatitis phenotype (the degree of skin thickening) of the animals, with blank gel used as a control.

[0058] Figure 4 , CKBA ointment was used to treat the atopic dermatitis animal model, which effectively improved the atopic dermatitis phenotype (the degree of skin thickening) of the animals, and a blank ointment was used as a control.

[0059] Figure 5 CKBA ointment was used to treat an animal model of atopic dermatitis, which significantly reduced the proportion of activated mast cells in the animal's skin. DETAILED DESCRIPTION

[0060] After in-depth research, the inventors have revealed for the first time that a pentacyclic triterpene structure-modified compound can effectively treat atopic dermatitis. The pentacyclic triterpene structure-modified compound can also be used to inhibit the activation of mast cells, especially the expression of mast cell activation marker CD107a and mast cell degranulation. On this basis, the present invention was completed.

[0061] the term

[0062] As used in the present invention, the "atopic dermatitis caused by mast cell activation and expression of the activation marker CD107a and degranulation effect" refers to a type of atopic dermatitis, the occurrence of which is closely related to the inflammatory response induced by mast cells.

[0063] As used in the present invention, the "mast cell degranulation" refers to the presence of secretory granules in the cytoplasm of mast cells, which contain heparin, histamine, eosinophil chemotactic factor, etc. When mast cells are stimulated, the substances in the granules are released by exocytosis; at the same time, leukotrienes synthesized in the cytoplasm are released.

[0064] The term "alkyl" used in the present invention refers to a straight or branched saturated aliphatic hydrocarbon group containing 1 to 4 carbon atoms (preferably 1 to 2 carbon atoms). For example, alkyl includes but is not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl.

[0065] The term "alkenyl" as used herein includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon double bond and 2 to 4 carbon atoms, preferably 2 to 3 carbon atoms.

[0066] The term "alkynyl" as used herein includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon triple bond and 2 to 4 carbon atoms, preferably 2 to 3 carbon atoms.

[0067] The term "halogen" as used herein refers to F, Cl, Br, or I.

[0068] The term "isomer" used in the present invention includes: geometric isomers, enantiomers, diastereomers (such as cis-trans isomers, conformational isomers).

[0069] The present invention uses The representation method of is well known to those skilled in the art, which indicates that the group R can be substituted at any one or more substitutable positions on the ring. Moreover, the selection of R can be different at different substitution positions.

[0070] The term "solvate" used in the present invention refers to a compound that carries solvent molecules, for example, the solvate may be a hydrate.

[0071] In the present invention, the term "comprising" means that various components can be used together in the mixture or composition of the present invention. Therefore, the terms "consisting mainly of" and "consisting of" are included in the term "comprising".

[0072] In the present invention, "pharmaceutically acceptable" ingredients are substances that are suitable for use in humans and / or animals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), that is, substances with a reasonable benefit / risk ratio.

[0073] In the present invention, "pharmaceutically acceptable carrier" is a pharmaceutically or food-acceptable solvent, suspending agent or excipient for delivering the compound of formula (I), isomer, solvate, precursor, or pharmaceutically acceptable salt thereof to animals or humans. The carrier may be liquid or solid.

[0074] In the present invention, unless otherwise specified, the "culture medium" is a culture medium suitable for the growth of mast cells, in which some factors can be added to make the mast cells differentiate, mature and activate (simulating the mast cell maturation and activation process in vivo). For example, m-IL3 and m-SCF are added to make them mature, and anti-DNP and DNP-HSA are added on this basis, so that the cells differentiate into mature mast cells expressing CD117 and FcεRIα and expressing the activation marker CD107a and degranulation effect occurs.

[0075] Compound

[0076] The present invention provides a compound as shown in structural formula (I).

[0077] The present invention also includes isomers, solvates, precursors, or pharmaceutically acceptable salts thereof of the compound of formula (I), as long as they also have the same or substantially the same functions as the compound of formula (I). The "pharmaceutically acceptable salt" refers to a salt formed by the reaction of a compound with an inorganic acid, an organic acid, an alkali metal or an alkaline earth metal. These salts include (but are not limited to): (1) salts formed with the following inorganic acids: such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid; (2) salts formed with the following organic acids, such as acetic acid, oxalic acid, succinic acid, tartaric acid, methanesulfonic acid, maleic acid, or arginine. Other salts include salts formed with alkali metals or alkaline earth metals (such as sodium, potassium, calcium or magnesium) in the form of esters, carbamates, or other conventional "prodrugs". The compound has one or more asymmetric centers. Therefore, these compounds may exist as racemic mixtures, individual enantiomers, individual diastereomers, diastereoisomer mixtures, cis or trans isomers.

[0078] The "precursor of a compound" refers to a compound of formula (I), or a salt or solution of a compound of formula (I) which undergoes metabolism or chemical reaction in the patient's body after being taken by an appropriate method.

[0079] As a preferred embodiment of the present invention, the compound has a structure shown in formula (II). The English name of the compound of formula (II) is 3-o-α-cyclohexanoyl-11-keto-β-boswellic acid, referred to as CKBA. Its molecular formula C 37 H 56 O 5 , molecular weight 581.

[0080] As an embodiment of the present invention, the compound may be AKBA, an analog of CKBA. However, CKBA is preferred.

[0081] Those skilled in the art should understand that, after knowing the structure of the compound of the present invention, the compound of the present invention can be obtained by a variety of methods well known in the art, using known raw materials, such as chemical synthesis or extraction from organisms (such as animals or plants), and these methods are all included in the present invention.

[0082] For example, as a method for preparing the compound represented by formula (I) of the present invention, the method comprises: using 11-carbonyl-β-acetyl boswellic acid as a raw material, replacing the AcO- group thereof with Group. More preferably, the preparation steps include: (i) using 11-carbonyl-β-acetyl boswellic acid (AKBA) as a raw material, reacting with a base (such as KOH) to obtain 11-carbonyl-β-boswellic acid; and (ii) reacting 11-carbonyl-β-boswellic acid with cyclohexanecarbonyl chloride to obtain the compound shown in formula (I). Other methods for preparing the compound of formula (I) are also included in the present invention, for example, using 11-carbonyl-β-boswellic acid (KBA) as a raw material, reacting it with cyclohexanecarbonyl chloride to directly obtain the compound shown in formula (I).

[0083] The synthesized compound can be further purified by column chromatography, high performance liquid chromatography, etc. In addition, it can also be further purified by crystallization. It should be understood that a variety of purification methods can be applied to the present invention.

[0084] Uses: Relieve or treat atopic dermatitis

[0085] In the present invention, it is firstly disclosed that the compound shown in the structural formula (I) has the function of relieving or treating atopic dermatitis, and the technical effect is excellent. Atopic dermatitis is an allergic skin inflammation. When the skin is dry and thickened, it is accompanied by a typical increase in the level of IgE in the body and obvious itching symptoms. Its pathogenesis has been proven to be extremely related to mast cells and basophils expressing high-affinity IgE receptors. This is completely different from the pathogenesis of diseases such as psoriasis, which are almost dominated by T cells and have nothing to do with IgE.

[0086] Through studies at the cellular level and animal disease models, the present inventors have demonstrated that CKBA has significant uses in treating atopic dermatitis.

[0087] Based on the new discovery of the inventors, the present invention discloses a new use of a pentacyclic triterpene structure-modified compound. The preferred compound of the present invention is CKBA. In vivo experiments can effectively improve the "atopic dermatitis" phenotype of mice. It can be used to prepare a drug for treating and / or preventing atopic dermatitis.

[0088] The present invention discloses a new medical use of a CKBA compound or an analog thereof (i.e., a compound of formula (I) of the present invention or an isomer, solvate or precursor thereof, or a pharmaceutically acceptable salt thereof), namely, use in the preparation of a drug for treating and / or preventing atopic dermatitis. Furthermore, the present invention also includes a drug for treating atopic dermatitis, wherein the active ingredient is CKBA or an analog thereof.

[0089] The CKBA compound or its analogues of the present invention are prepared in a conventional pharmaceutical method with pharmaceutically acceptable excipients to form an external dosage form. In a preferred embodiment, the weight content of the CKBA compound or its derivatives can be 0.01%-1.5%. It should be understood that the physician can also make appropriate dosage changes according to the actual clinical situation.

[0090] The present invention also provides a method for alleviating or treating atopic dermatitis, comprising: administering an effective amount of the compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof to a subject in need of treatment.

[0091] Use: Regulate mast cell activation

[0092] Mast cells originate from bone marrow hematopoietic stem cells and express mast cell-specific surface markers during maturation, such as FcεRI, CD117, etc. Mast cells function mainly through the stimulation of surface receptors or activating factors, releasing a variety of bioactive substances.

[0093] After activation, mast cells will highly express their surface marker CD107a and will also undergo significant degranulation, thereby participating in various allergic or inflammatory reactions.

[0094] The inventors found that CKBA can effectively reduce the proportion of mast cells expressing CD107a and the degranulation effect in in vitro experiments, and reduce the production of some bioactive substances.

[0095] Mast cells express the high-affinity receptor FcεRI that binds to IgE and can mediate its activation. Patients with atopic dermatitis have significantly elevated IgE levels in the peripheral blood and significantly increased mast cell infiltration in the skin lesions. At the same time, the allergy and inflammation-related bioactive substances secreted by mast cells in the patient's body also increase significantly, promoting the further development of inflammation.

[0096] The present invention aims at the pathogenesis of atopic dermatitis and adopts relevant pharmacological experimental methods to conduct in vivo and in vitro efficacy experiments of CKBA compounds in treating atopic dermatitis. The efficacy is studied from the aspects of mast cell induction differentiation, in vitro inhibition of activation efficiency, activation marker expression ability, ear thickness reduction, skin dryness, etc., to illustrate the medicinal use of CKBA compounds in treating atopic dermatitis.

[0097] In the embodiments of the present invention, experiments show that the use of CKBA compounds can effectively inhibit the expression of the activation marker CD107a by mast cells and reduce the degranulation effect of mast cells (such as reducing the release of β-hexosaminidase); it can help reduce the skin thickness of atopic dermatitis mouse models, reduce the dryness of the skin, and improve the atopic dermatitis phenotype of mice.

[0098] Based on the new discovery of the inventors, the present invention also provides the use of the compound represented by formula (I) or its isomer, solvate or precursor, or their pharmaceutically acceptable salts, for preparing a composition for inhibiting the activation of mast cells. The composition can be a cell culture medium or a pharmaceutical composition. The inhibition of mast cell activation is: inhibiting mast cell activation to highly express CD107a; and / or inhibiting mast cell degranulation effect (releasing β-hexosaminidase)

[0099] After mast cells mature, they express transmembrane receptors FcεRIα on their cell surface. In the presence of IgE, the Fc segment of IgE can bind to the receptor FcεRIα with high affinity, thereby stimulating direct activation of mast cells. Activated mast cells highly express surface receptor CD107a, which is part of the mast cell granule membrane. During mast cell activation, CD107a can be transported to the cell surface and synergize with other membrane molecules to promote the efflux and secretion of mast cell granules, releasing a variety of bioactive molecules such as histamine, leukotrienes and other mediators, thereby participating in physiological and pathological processes such as allergic reactions and inflammatory reactions.

[0100] Degranulation refers to the process in which the biologically active molecules contained in mast cell granules are released to the outside of the cell through the efflux mechanism of the mast cell membrane. Mast cell granules contain a variety of biologically active molecules, such as histamine, leukotrienes, proteases, etc. The release of these molecules is a key step in the physiological and pathological processes such as mast cell-mediated inflammatory reactions and allergic reactions. Therefore, it is necessary to develop drugs that regulate mast cell activation.

[0101] The present invention discloses for the first time that the compound represented by formula (I) or its isomers, solvates or precursors, or their pharmaceutically acceptable salts have the ability to regulate mast cell activation, expression of CD107a and degranulation effect, thus providing an effective way to regulate the differentiation of such cell subpopulations.

[0102] Composition

[0103] The present invention also provides a pharmaceutical composition for treating atopic dermatitis, comprising: (a) an effective amount of a compound of formula (I), or its isomers, solvates, precursors, or pharmaceutically acceptable salts thereof; and (b) a pharmaceutically acceptable carrier or excipient.

[0104] In the present invention, the pharmaceutical composition may contain 0.01-3% by weight of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutical composition may contain 0.02-2% by weight of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof; more preferably, the pharmaceutical composition may contain 0.05-1.5% by weight of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

[0105] The pharmaceutical composition of the present invention can be prepared into a variety of dosage forms, such as gel, ointment, aerosol, tablet, capsule, powder, granule, solution, or suspension.

[0106] From the standpoint of ease of preparation and administration, the preferred pharmaceutical composition is a solid or semi-solid composition. The compound of the present invention or its pharmaceutical composition can also be stored in a sterile device suitable for application or instillation.

[0107] When used to relieve or treat atopic dermatitis, it is preferred that the pharmaceutical composition is administered externally; for example, including but not limited to: ointments (such as creams, pastes), gels, foams, sprays, powders, creams; more preferably, the pharmaceutical composition is in the form of ointments (such as creams, pastes). As a preferred embodiment of the present invention, the pharmaceutical composition is an ointment.

[0108] The inventors unexpectedly discovered that a specially formulated ointment has a synergistic effect on the efficacy of the compound described in formula (I). The ointment preferably comprises the following components: the compound described in formula (I); and white vaseline, light liquid paraffin, isopropyl myristate, and vitamin E.

[0109] Taking CKBA as the research object, the inventors compared the ointment and the gel and found that although the CKBA in both is active, the components in the ointment have a significant promoting effect on the effect of the CKBA compound, which helps to exert the activity of CKBA in the lesion site. The therapeutic effect on atopic dermatitis is unexpected and has great clinical application value.

[0110] Taking CKBA as the research object, the inventors compared the ointment with the solution. In terms of effective action time, the ointment of the present invention is much longer than the solution.

[0111] The effective dosage of the compound of formula (I) as an active ingredient may vary with the mode of administration and the severity of the disease to be treated. For example, the compound of the present invention may be administered at a dosage of about 0.0001-500 mg / kg, preferably 0.001-300 mg / kg, more preferably 0.01-200 mg / kg of animal body weight per day, to obtain satisfactory results, preferably in 1-3 divided doses per day, or in a sustained release form. This dosage regimen may be adjusted to provide the best therapeutic response. For example, several divided doses may be administered per day, or the dosage may be reduced proportionally, depending on the urgency of the treatment condition.

[0112] In addition, the compound of formula (I), or its isomer, solvate, precursor, or pharmaceutically acceptable salt thereof can also be added to an appropriate culture medium for regulating the differentiation of mast cells. In some preferred embodiments, the concentration of the compound in the culture medium is 1 to 10 μM; preferably 2 to 8 μM. The amount of addition can be adjusted according to actual conditions.

[0113] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.

[0114] Example 1. Preparation of gel medicine containing CKBA

[0115] A certain amount of CKBA compound was taken to prepare a gel drug according to the formula in Table 1.

[0116] Table 1

[0117]

[0118]

[0119] Example 2: Preparation of ointment containing CKBA

[0120] A certain amount of CKBA compound and preferably several auxiliary preparations are taken to prepare 15 grams of ointment according to the formula in Table 3.

[0121] Prepare 0.5% CKBA ointment (15 g) as shown in Table 2.

[0122] Table 2

[0123] CKBA 75mg 0.5% White Vaseline 11.172g 74.48% Light liquid paraffin 0.75g 5% Isopropyl myristate 3g 20% Vitamin E 3mg 0.02% Total weight 15g -

[0124] 1% CKBA ointment (15 g) was prepared as shown in Table 3.

[0125] Table 3

[0126] CKBA 0.15g 1.0% White Vaseline 11.097g 73.98% Light liquid paraffin 0.75g 5% Isopropyl myristate 3g 20% Vitamin E 3mg 0.02% Total weight 15g -

[0127] White vaseline: obtained from Nanchang Baiyun Pharmaceutical Co., Ltd., batch number F20209990088.

[0128] Light liquid paraffin: obtained from Nanchang Baiyun Pharmaceutical Co., Ltd., batch number F20209990087.

[0129] Example 3: Experiment on the inhibition of mast cell degranulation by CKBA compounds in vitro

[0130] Male C57BL / 6 mice aged 6 to 8 weeks were selected, and the leg bones of the mice were removed under sterile conditions in a clean bench, and the femur and tibia were separated. The red bone marrow was flushed out with a 10ml syringe filled with 10ml of RPMI 1640 medium without additives, and lysate was added to obtain bone marrow cells. Under the induction conditions of m-IL3 and m-SCF, the cells were induced to differentiate into CD117+FcεRIα+ mast cells for four weeks.

[0131] Four weeks later, one day in advance, the mast cells were coated with anti-DNP (final concentration was 1 μg / ml) in RPMI 1640 + 10% FBS medium, and the mast cells were resuspended and plated in a 96-well plate. A 96-well round-bottom plate was selected, and BMMC was 1*10 5 cells / well, 100 μl per well, coating at 4°C for 16 h.

[0132] After 16 hours, centrifuge at 400g for 5 minutes, discard the supernatant, add CKBA (5μM, dissolved in DMSO) and the same volume of DMSO, as well as DNP-HSA (final concentration 1μg / ml), keep the total system still 100μl, put it in a 37℃ incubator for 30 minutes, stimulate mast cell degranulation, set up 6 duplicate wells in each group, and collect the cells with 5μM CKBA concentration, and use 120kV electron microscope to photograph the degranulation phenomenon after treatment. Centrifuge again after the stimulation, take a new 96-well flat-bottom plate, add 100ul of PNAG solution to each well, take 50μl of the above degranulation supernatant, add it to the PNAG solution, put it in a 37℃ incubator for 60 minutes, and detect the level of β-hexosaminidase (supernatant) released by degranulation.

[0133] Add 150 μl of 0.1% Triton X-100 (Tyrode's buffer) to the remaining 50 μl of cell suspension, mix well to lyse the cells (by blowing several times), and completely release the β-hexosaminidase in the cells. Place the suspension in a centrifuge and centrifuge at 4°C for 5 min.

[0134] Take a new 96-well flat-bottom plate and add 100 μl / well of PNAG solution; aspirate 50 μl of the supernatant of the lysed cells and add them to the PNAG solution respectively, put them in a 37°C incubator for 60 minutes, and detect the level of β-hexosaminidase (in cell pellet) in the cells.

[0135] After the above-mentioned β-hexosaminidase reacted with the substrate PNAG for 60 minutes, 50 μl / well of 0.4M glycine solution was added to terminate the reaction. The intensity of the yellow color indicated the degree of release, and the absorbance was detected at 405 nm (610 nm as a reference) using an enzyme reader. The degree of mast cell degranulation was calculated according to the formula: (2×(supernatant-plate blank)) / (1 / 2(total supernatant-plate blank))+(4×(lysates-plate blank)).

[0136] like Figure 1 The results showed that CKBA compounds could effectively reduce the formation of vesicles in the cytoplasm of mast cells, retain dense and uniform granules in the cytoplasm, and significantly inhibit the release of β-hexosaminidase from activated mast cells.

[0137] Example 4: Experiment on the inhibition of mast cell activation and high expression of CD107a by CKBA compounds in vitro

[0138] Male C57BL / 6 mice aged 6 to 8 weeks were selected, and the leg bones of the mice were removed under sterile conditions in a clean bench, and the femur and tibia were separated. The red bone marrow was flushed out with a 10ml syringe filled with 10ml of RPMI 1640 medium without additives, and lysate was added to obtain bone marrow cells. Under the induction conditions of m-IL3 and m-SCF, the cells were induced to differentiate into CD117+FcεRIα+ mast cells for four weeks.

[0139] Four weeks later, one day in advance, the mast cells were coated with anti-DNP (final concentration was 1 μg / ml) in RPMI 1640 + 10% FBS medium, and the mast cells were resuspended and plated in a 96-well plate. A 96-well round-bottom plate was selected, and BMMC was 1*10 5 cells / well, 100 μl per well, coating at 4°C for 16 h.

[0140] After 16 hours, centrifuge at 400g for 5 minutes, discard the supernatant, add CKBA (5μM, dissolved in DMSO) and the same volume of DMSO, as well as DNP-HSA (final concentration 1μg / ml), keep the total system still 100μl, put it in a 37℃ incubator for 30 minutes to stimulate mast cell degranulation, and set 6 replicates for each group. Discard the supernatant, and detect the expression of CD107a in mast cells by flow cytometry.

[0141] like Figure 2 The results showed that CKBA compounds could significantly reduce the expression of CD107a on the surface of activated mast cells.

[0142] Example 5: Experiment on the treatment of atopic dermatitis in mice using a pharmaceutical preparation of CKBA compound

[0143] 1. Animal model of atopic dermatitis

[0144] C57BL / 6J mice weighing >20g and aged 8-12 weeks were selected and kept in a stable environment for one week before the experiment. The mice were anesthetized by intraperitoneal injection of 2% chloral hydrate at a dose of 0.2-0.3ml / 10kg body weight. After anesthesia, the mice were placed on the operating table in a prone position. The hair around the ears of the mice was shaved with an animal razor and the hair was removed with ddH2O. 2O was wiped clean, and the thickness of the mouse ears was measured with a vernier caliper. The required Calcipotriol (MC903) solution was calculated and prepared into the required volume according to the amount applied for 16 consecutive days. A micropipette with a range of 100 μl was used. The experimental group absorbed 25 μl of 45 μM MC903 solution, and the control group absorbed 25 μl of anhydrous ethanol, and evenly applied to both sides of the mouse ears. After application, the mouse was placed on the operating table in a prone position to ensure that the MC903 on the mouse ears was not scratched. At the same time, the ventilation system of the operating table was turned on to promote the volatilization of anhydrous ethanol on the mouse ear skin, and an atopic dermatitis animal model was successfully constructed.

[0145] 2. CKBA gel preparation

[0146] Fifteen mice with atopic dermatitis were divided into two groups: a blank gel group (Table 1, but without gel addition) and a 1.0% CKBA (Table 1) treatment group, with 5 test mice in each group. The affected area was determined, photographed and recorded, and the hair was shaved, ready for application of control gel (blank gel) or CKBA gel.

[0147] On the fifth day of inducing atopic dermatitis in mice with MC903, the mice had obvious scratching reactions and the skin thickness was gradually increasing. At this time, CKBA gel, empty control gel without CKBA, and positive control gel were applied to the mice and continued to be applied until the 15th day. Photos were taken to record the ear thickness.

[0148] like Figure 3 (Day 1 in the figure is the first day of induction with calcipotriol). The blank gel group (Vehicle) had significantly thickened ears on day 15, with obvious redness and swelling, indicating a worsening of the disease. For the animals in the 1% CKBA gel group, the redness and swelling of the ear skin were reduced and the thickness was significantly reduced on day 15 after modeling (*P<0.05).

[0149] according to Figure 3 , the ear thickness of the animals in the 1% CKBA gel group was significantly reduced, but did not return to the original level. In other words, the ear thickness was reduced but not completely eliminated.

[0150] 3. CKBA ointment preparation

[0151] 15 mice with atopic dermatitis were divided into 3 groups: blank ointment group, 0.5% CKBA treatment group, and 1.0% CKBA treatment group, with 5 experimental mice in each group. The site of disease was determined, photographed and recorded, and the hair was shaved for application of control ointment (blank ointment) or CKBA ointment.

[0152] On the fifth day of inducing atopic dermatitis in mice with MC903, the mice had obvious scratching reactions and the skin thickness was gradually increasing. At this time, CKBA ointment, empty control ointment without CKBA, and positive control ointment were applied to the mice, and the application was continued until the 15th day. On the last day, photos were taken to record the thickness of the skin and ears at the drug administration site, and then the mice were killed by cervical scissors, the skin at the diseased site was cut, paraffin sections were made, and toluidine blue staining was performed to observe the activation of mast cells in the mouse ears.

[0153] Observe the disease phenotype (extent of hair graying) in animal models, such as Figure 4 In the blank ointment group (Vehicle), the ear thickness was significantly thickened on the 15th day, with obvious redness and swelling, showing aggravation of the disease. In the 0.5% CKBA group, the ear skin redness and swelling were reduced and the thickness decreased on the 15th day; in the 1% CKBA group, the ear skin redness and swelling were reduced and the thickness decreased significantly on the 15th day after modeling (**P<0.01), only slightly thicker than before modeling, and the thickening was basically eliminated.

[0154] The activation ratio of mast cells infiltrating the skin of animals (1% CKBA ointment group) was tested. The results are as follows Figure 5 On day 15, the proportion of degranulated mast cells in the ear tissue of animals in the 1% CKBA group was significantly reduced (***P<0.001).

[0155] The above results show that CKBA compounds can effectively improve the phenotype of atopic dermatitis. In terms of dosage form, the gel preparation is effective, and the components in the ointment preparation have a significant synergistic effect on the effect of the CKBA compound, which helps CKBA to exert its activity in the lesion site, and the therapeutic effect on atopic dermatitis is unexpected.

[0156] Comparing the ointment preparation with the solution (dissolved in DMSO), the ointment of the present invention has a much longer effective action time than the solution.

[0157] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

Claims

1. Use of the compound represented by formula (I) or its isomer, solvate or precursor, or pharmaceutically acceptable salt thereof, for preparing a pharmaceutical composition for relieving or treating atopic dermatitis; in, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen.

2. The use according to claim 1, characterized in that The atopic dermatitis is: Atopic dermatitis caused by mast cell activation leading to degranulation; and / or Mast cell activation leads to high expression of CD107a as the etiology of atopic dermatitis.

3. Use of the compound represented by formula (I) or its isomer, solvate or precursor, or pharmaceutically acceptable salt thereof, for preparing a composition for inhibiting mast cell activation; in, R is independently selected from the group consisting of hydrogen, hydroxy, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen.

4. The use according to claim 3, characterized in that The inhibition of mast cell activation is: Inhibit the expression of CD107a on the surface of mast cells; and / or Inhibits mast cell degranulation.

5. The use according to any one of claims 1 to 4, characterized in that: The composition is an external dosage form; preferably, the composition is selected from: ointment, gel, foam, spray, powder, cream; more preferably, the dosage form of the pharmaceutical composition is ointment.

6. The use according to claim 5, characterized in that The composition is an ointment, comprising: (a) a compound represented by formula (I) or an isomer, solvate or precursor thereof, or a pharmaceutically acceptable salt thereof; and (b) White petrolatum, light liquid paraffin, isopropyl myristate, vitamin E.

7. The use according to claim 6, characterized in that The ointment comprises: (a) Compound: 0.3 to 3 parts by weight, preferably 0.4 to 2 parts by weight; White vaseline: 65-85 parts by weight, preferably 68-82 parts by weight; Light liquid paraffin: 2-9 parts by weight, preferably 3-8 parts by weight; Isopropyl myristate: 12 to 30 parts by weight, preferably 15 to 25 parts by weight; Vitamin E: 0.01-0.05 parts by weight, preferably 0.012-0.04 parts by weight.

8. A pharmaceutical composition for alleviating or treating atopic dermatitis, which is an ointment, comprising: (a) a compound represented by formula (I) or an isomer, solvate or precursor thereof, or a pharmaceutically acceptable salt thereof; and (b) white petrolatum, light liquid paraffin, isopropyl myristate, vitamin E; Preferably, the ointment comprises: (a) Compound: 0.3 to 3 parts by weight, preferably 0.4 to 2 parts by weight; White vaseline: 65-85 parts by weight, preferably 68-82 parts by weight; Light liquid paraffin: 2 to 9 parts by weight, preferably 3 to 8 parts by weight; Isopropyl myristate: 12 to 30 parts by weight, preferably 15 to 25 parts by weight; Vitamin E: 0.01-0.05 parts by weight, preferably 0.012-0.04 parts by weight.

9. A method for preparing a pharmaceutical composition for relieving or treating atopic dermatitis, comprising: Mixing (a) the compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof, and (b) white vaseline, light liquid paraffin, isopropyl myristate and vitamin E to prepare an ointment; Preferably, the ointment comprises: (a) Compound: 0.3 to 3 parts by weight, preferably 0.4 to 2 parts by weight; White vaseline: 65-85 parts by weight, preferably 68-82 parts by weight; Light liquid paraffin: 2 to 9 parts by weight, preferably 3 to 8 parts by weight; Isopropyl myristate: 12 to 30 parts by weight, preferably 15 to 25 parts by weight; Vitamin E: 0.01-0.05 parts by weight, preferably 0.012-0.04 parts by weight.

10. A method for inhibiting mast cell activation, characterized in that: The method comprises: treating mast cells with a compound represented by formula (I) or its isomer, solvate or precursor, or a pharmaceutically acceptable salt thereof, thereby inhibiting the activation of mast cells; Preferably, the inhibition of mast cell activation is: Inhibit mast cell activation; and / or Inhibits mast cell activation and degranulation.